Search

Your search keyword '"Hocking, Jane S."' showing total 1,336 results
Start Over Author "Hocking, Jane S."
1,336 results on '"Hocking, Jane S."'

108. Mycoplasma genitalium Incidence, Organism Load, and Treatment Failure in a Cohort of Young Australian Women

Author

Walker, Jennifer, Fairley, Christopher K., Bradshaw, Catriona S., Tabrizi, Sepehr N., Twin, Jimmy, Chen, Marcus Y., Taylor, Nicole, Donovan, Basil, Kaldor, John M., McNamee, Kathleen, Urban, Eve, Walker, Sandra, Currie, Marian, Birden, Hudson, Bowden, Francis J., Gunn, Jane, Pirotta, Marie, Gurrin, Lyle, Harindra, Veerakathy, Garland, Suzanne M., and Hocking, Jane S.

Published
2013
Full Text
View/download PDF

122. Safe Sex Messages Within Dating and Entertainment Smartphone Apps: A Review

Author

Huang, Evelyn Tzu-Yen, Williams, Henrietta, Hocking, Jane S, and Lim, Megan SC

Subjects
Information technology, T58.5-58.64, Public aspects of medicine, RA1-1270
Abstract

BackgroundSmartphone apps provide a new platform for entertainment, information distribution, and health promotion activities, as well as for dating and casual sexual encounters. Previous research has shown high acceptability of sexual health interventions via smartphone apps; however, sexual health promotion apps were infrequently downloaded and underused. Integrating sexual health promotion into established apps might be a more effective method. ObjectiveThe objective of our study was to critically review popular sex-related apps and dating apps, in order to ascertain whether they contain any sexual health content. MethodsPart 1: In January 2015, we used the term “sexual” to search for free apps in the Apple iTunes store and Android Google Play store, and categorized the sexual health content of the 137 apps identified. Part 2: We used the term “dating” to search for free geosocial-networking apps in the Apple iTunes and Android Google Play stores. The apps were downloaded to test functionality and to determine whether they included sexual health content. ResultsPart 1: Of the 137 apps identified, 15 (11.0%) had sexual health content and 15 (11.0%) contained messages about sexual assault or violence. The majority of the apps did not contain any sexual health content. Part 2: We reviewed 60 dating apps: 44 (73%) targeting heterosexual users, 9 (15%) targeting men who have sex with men (MSM), 3 (5%) targeting lesbian women, and 4 (7%) for group dating. Only 9 dating apps contained sexual health content, of which 7 targeted MSM. ConclusionsThe majority of sex-related apps and dating apps contained no sexual health content that could educate users about and remind them of their sexual risks. Sexual health practitioners and public health departments will need to work with app developers to promote sexual health within existing popular apps. For those apps that already contain sexual health messages, further study to investigate the effectiveness of the content is needed.

Published
2016
Full Text
View/download PDF

134. Controversies and evidence on Chlamydia testing and treatment in asymptomatic women and men who have sex with men: a narrative review

Author

HTA Onderzoek Team 1, Global Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Dukers-Muijrers, Nicole H.T.M., Evers, Ymke J., Hoebe, Christian J.P.A., Wolffs, Petra F.G., de Vries, Henry J.C., Hoenderboom, Bernice, van der Sande, Marianne A.B., Heijne, Janneke, Klausner, Jeffrey D., Hocking, Jane S., van Bergen, Jan, HTA Onderzoek Team 1, Global Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Dukers-Muijrers, Nicole H.T.M., Evers, Ymke J., Hoebe, Christian J.P.A., Wolffs, Petra F.G., de Vries, Henry J.C., Hoenderboom, Bernice, van der Sande, Marianne A.B., Heijne, Janneke, Klausner, Jeffrey D., Hocking, Jane S., and van Bergen, Jan

Published
2022

135. Comparison of gastrointestinal side effects from different doses of azithromycin for the treatment of gonorrhoea

Author

Ong, Jason J., Aguirre, Ivette, Unemo, Magnus, Kong, Fabian Y. S., Fairley, Christopher K., Hocking, Jane S., Chow, Eric P. F., Tieosapjaroen, Warittha, Ly, Jenny, Chen, Marcus Y., Ong, Jason J., Aguirre, Ivette, Unemo, Magnus, Kong, Fabian Y. S., Fairley, Christopher K., Hocking, Jane S., Chow, Eric P. F., Tieosapjaroen, Warittha, Ly, Jenny, and Chen, Marcus Y.

Abstract

OBJECTIVES: Azithromycin is commonly used to treat Neisseria gonorrhoeae. We compared its gastrointestinal side effects using 1 g single, 2 g single or 2 g split (i.e. 1 g plus 1 g 6-12 h later) dosing, representing our clinic's changing guidelines over the study period. METHODS: We recruited consecutive sexual health clinic patients who received azithromycin (and 500 mg ceftriaxone) for uncomplicated gonorrhoea. Each patient received a text message 48 h after their attendance to complete a questionnaire. RESULTS: Patients received 1 g single (n = 271), 2 g single (218) or 2 g split (105) doses. Vomiting was less common for 1 g versus 2 g single dose [1.1% versus 3.7%; risk difference (RD): -2.6%; 95% CI: -0.2 to -5.4] and 2 g split versus 2 g single dose (0.9% versus 3.7%; RD: -2.8%; 95% CI: -0.3 to -5.8). Nausea was less common for 1 g versus 2 g single dose (13.7% versus 43.1%; RD: -29.5%; 95% CI: -21.7 to -37.2) and 2 g split versus 2 g single dose (16.4% versus 43.1%; RD: -26.8; 95% CI: -17.2 to -36.3). Diarrhoea was less common for 1 g versus 2 g single dose (25.5% versus 50.9%; RD: -25.5%; 95% CI: -17.0 to -33.9) and 2 g split versus 2 g single dose (30.9% versus 50.9%; RD: -20.0; 95% CI: -9.1 to -30.9). Almost all were willing to retake the same dosing for gonorrhoea in the future: 97% for 1 g single; 94% for 2 g single; and 97% for 2 g split dose. CONCLUSIONS: Azithromycin 2 g split dose for gonorrhoea resulted in significantly less vomiting, nausea and diarrhoea than a 2 g single dose., Funding agency:National Health and Medical Research Council (NHMRC) of Australia GNT1193955 GNT1172873 GNT1172900 GNT1136117

Published
2022
Full Text
View/download PDF

136. Optimisation of treatments for oral Neisseria gonorrhoeae infection : Pharmacokinetics Study (STI-PK project) - study protocol for non-randomised clinical trial

Author

Kong, Fabian Y. S., Unemo, Magnus, Lim, Shueh H., Latch, Ngaire, Williamson, Deborah A., Roberts, Jason A., Wallis, Steven C., Parker, Suzanne L., Landersdorfer, Cornelia B., Yap, Tami, Fairley, Christopher K., Chow, Eric P. F., Lewis, David A., Hammoud, Mohamed A., Hocking, Jane S., Kong, Fabian Y. S., Unemo, Magnus, Lim, Shueh H., Latch, Ngaire, Williamson, Deborah A., Roberts, Jason A., Wallis, Steven C., Parker, Suzanne L., Landersdorfer, Cornelia B., Yap, Tami, Fairley, Christopher K., Chow, Eric P. F., Lewis, David A., Hammoud, Mohamed A., and Hocking, Jane S.

Abstract

INTRODUCTION: Neisseria gonorrhoeae infections are common and incidence increasing. Oropharyngeal infections are associated with greater treatment failure compared with other sites and drive transmission to anogenital sites through saliva. Gonococcal resistance is increasing and new treatments are scarce, therefore, clinicians must optimise currently available and emerging treatments in order to have efficacious therapeutic options. This requires pharmacokinetic data from the oral cavity/oropharynx, however, availability of such information is currently limited. METHODS AND ANALYSIS: Healthy male volunteers (participants) recruited into the study will receive single doses of either ceftriaxone 1 g, cefixime 400 mg or ceftriaxone 500 mg plus 2 g azithromycin. Participants will provide samples at 6-8 time points (treatment regimen dependent) from four oral sites, two oral fluids, one anorectal swab and blood. Participants will complete online questionnaires about their medical history, sexual practices and any side effects experienced up to days 5-7. Saliva/oral mucosal pH and oral microbiome analysis will be undertaken. Bioanalysis will be conducted by liquid chromatography-mass spectrometry. Drug concentrations over time will be used to develop mathematical models for optimisation of drug dosing regimens and to estimate pharmacodynamic targets of efficacy. ETHICS AND DISSEMINATION: This study was approved by Royal Melbourne Hospital Human Research Ethics Committee (60370/MH-2021). The study results will be submitted for publication in peer-reviewed journals and reported at conferences. Summary results will be sent to participants requesting them. All data relevant to the study will be included in the article or uploaded as supplementary information. TRIAL REGISTRATION NUMBER: ACTRN12621000339853., Funding agencies:National Health and Medical Research Council (NHMRC) of Australia APP1181057 APP2007007 Advancing Queensland Clinical Fellowship APP2009736National Health and Medical Research Council (NHMRC) of Australia GNT1172873

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results